MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM). The primary hypothesis of the study is that single doses of MK-1006 will be sufficiently safe and well tolerated, based on the assessment of clinical and laboratory evaluations and adverse experiences, in Japanese participants with T2DM.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Japanese male or female between 20 to 64 years of age

• Diagnosis of type 2 diabetes

• Patient is being treated with diet and exercise alone or single oral anti-hyperglycemic agent

Exclusion Criteria:

• Subject has a history of type 1 diabetes mellitus

• Subject has a clinical diagnosis of glaucoma

• Subject has donated blood or participated in another clinical study in the past 12 weeks

• Subject is a regular user of any illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months